Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi...

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer ( Dr Friederike Schlurmann, Dr Nabil Adra, Dr Emmanuel Antonarakis and Dr Hiroshi Kitamura )

Remote genetic testing has the potential to increase the uptake of testing in...

Dr Bruce Montgomery - University of Washington, Seattle, USA

Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems ( Dr Bruce Montgomery - University of Washington, Seattle, USA )

Stockholm3 offers a promising avenue for personalised risk-based prostate...

Dr Scott Eggener - The University of Chicago, Chicago, USA

Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis ( Dr Scott Eggener - The University of Chicago, Chicago, USA )

Cabozantinib and atezolizumab show more efficacy compared to second NHT in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Baseline characteristics of patients with PSMA-PET–positive and –negative...

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

Baseline characteristics of patients with PSMA-PET–positive and –negative disease with high-risk BCR after radical RP ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

Enfortumab vedotin in combination with pembrolizumab is a potential new...

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

Personalised systemic treatment in advanced prostate cancer

Dr Karim Fizazi - Institute Gustave Roussy, Villejuif, France

Personalised systemic treatment in advanced prostate cancer ( Dr Karim Fizazi - Institute Gustave Roussy, Villejuif, France )

World Bladder Cancer Patient Coalition

Dr Lydia Makaroff - President, World Bladder Cancer Patient Coalition, Oxford...

World Bladder Cancer Patient Coalition ( Dr Lydia Makaroff - President, World Bladder Cancer Patient Coalition, Oxford, UK )

DNA methylation profile of prostate cancer aggressiveness in Ghana

Dr Alexandra Lindsey Djomkam Zune - West African Centre for Cell Biology of...

Latest developments in the treatment of bladder cancer

Dr Alison Birtle, Dr Ignacio Durán, Dr Friederike Schlürmann, Dr Yohann Loriot...

Latest developments in the treatment of bladder cancer ( Dr Alison Birtle, Dr Ignacio Durán, Dr Friederike Schlürmann, Dr Yohann Loriot and Dr Peter Goebell )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer